Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma.

被引：0
|
作者：
Eustace, A. J.
Kennedy, S.
Larkin, A.
Mahgoub, T.
Tryfonopoulos, D.
O'Driscoll, L.
Clynes, M.
Crown, J.
O'Donovan, N.
机构：
[1] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland
[2] St Vincents Univ Hosp, Dublin 4, Ireland
[3] St Vincents Univ Hosp, Dublin 4, Ireland
[4] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland
[5] Irish Clin Oncol Res Grp & Mol Therapeut Canc, Dublin, Ireland
[6] Dublin City Univ, Mol Therapeut Canc Ireland, Natl Inst Cellular Biotechnol, Dublin 9, Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.8578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8578
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Predictive biomarkers of ipilimumab toxicity in metastatic melanoma.
    Gowen, Michael
    Tchack, Jeremy
    Zhou, Hua
    Giles, Keith Michael
    Paschke, Scott
    Moran, Una
    Fenyo, David
    Tsirigos, Aristotelis
    Pacold, Michael
    Pavlick, Anna C.
    Krogsgaard, Michelle
    Osman, Iman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Treatment with vemurafenib in patients with metastatic melanoma.
    Ocvirk, Janja
    Boc, Marko
    Mesti, Tanja
    Rebersek, Martina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Metastatic uveal melanoma. Prophylaxis and treatment
    Bechrakis, NE
    Scheibenbogen, C
    Schmittel, A
    Servetopoulou, F
    Foerster, MH
    Keilholz, U
    [J]. OPHTHALMOLOGE, 2002, 99 (05): : 333 - 337
  • [4] Biomarkers of treatment effect in a phase II trial of velimogene aliplasmid in patients with metastatic melanoma.
    Wloch, Mary K.
    Kharkevitch, Dmitri D.
    Chu, Alice
    Schulte, John
    Smith, Larry R.
    Kenney, Richard T.
    Rolland, Alain
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Metastatic malignant melanoma. Successfull treatment with ipilimumab
    Jansen, T.
    Bruch-Gerharz, D.
    Reifenberger, J.
    Schulte, K. W.
    [J]. HAUTARZT, 2013, 64 (04): : 228 - +
  • [6] The use of pembrolizumab for the treatment of metastatic uveal melanoma.
    Kottschade, Lisa A.
    McWilliams, Robert R.
    Markovic, Svetomir
    Block, Matthew Stephen
    Bisneto, Jose Villasboas
    Pham, Anthony QuocAnh
    Dronca, Roxana Stefania
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Promising predictive biomarkers for immunotherapy in metastatic melanoma
    Nyakas, Marta
    Aamdal, Elin
    Guren, Tormod
    Aamdal, Steinar
    Jacobsen, Kari Dolven
    Brunsvig, Paal
    Tasken, Kristin Austlid
    Maelandsmo, Gunhild
    Yndestad, Arne
    Halvorsen, Bente
    Aukrust, Paal
    Ueland, Thor
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [8] Combined treatment with dacarbazine, cisplatin and interferon a in metastatic melanoma.
    Tessier, MH
    Mansat, E
    Legoux, B
    Litoux, P
    Dreno, B
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1996, 123 (09): : 538 - 542
  • [9] Drug targets and predictive biomarkers in the management of metastatic melanoma
    Thumar, Jaykumar
    Giesen, Eva
    Kluger, Harriet M.
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2012, 5 : 139 - 148
  • [10] Immunotherapy disparities in metastatic melanoma.
    Oliver, Thomas
    Pezzi, Todd A.
    Pezzi, Ashley E.
    Shreders, Amanda
    Dao, Henry
    Crozier, Jennifer A.
    Pezzi, Christopher
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345